Entera Bio

CompanyIsrael

Entera Bio develops 2 assets, the furthest approved (teriparatide in fractures). Mostly peptide acting on PTH1R; based in Israel.

Assets
2
Furthest
Approved
Trials
4
Signals
0

Pipeline

2

  • teriparatide

    Recombinant parathyroid hormone receptor agonist promoting bone formation

    ApprovedPeptidePTH1Rfractureship fracture

  • EBP05

    Oral recombinant human parathyroid hormone fragment (1-34) acting as a PTH1R agonist.

    Phase 2PeptidePTH1Rhypoparathyroidismosteoporosis

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • Trials4
  • Similar companies6

Updated 7 Oct 2026 · 43 sources

Intelligence